This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
June 20, 2022
Börje Haraldsson appointed CEO of Oncorena AB
June 17, 2022
Carisma Therapeutics to Host Webcast on Phase 1 Clinical Trial of Engineered Macrophage Therapy
June 16, 2022
BONESUPPORT achieves private coverage in South Africa
June 16, 2022
Vicore announces first human dosed with novel ATRAG, C106
June 14, 2022
Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434
June 10, 2022
Fusion Pharmaceuticals And Niowave Announce Actinium-225 Collaboration And Supply Agreement
June 10, 2022
Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting
June 10, 2022
Precirix presents preclinical data of its FAP-targeting compound at the SNMMI annual meeting
June 08, 2022
Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
June 03, 2022
Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients